Navigation Links
Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer
Date:5/31/2009

Women should seek alternatives to SSRIs for hot flashes, studies suggest

SUNDAY, May 31 (HealthDay News) -- Common antidepressants that many breast cancer survivors use to dampen the hot flashes caused by taking tamoxifen may actually boost the odds of the disease's return, new research warns.

The finding was presented this weekend at the American Society of Clinical Oncology's annual meeting, in Orlando, Fla.

But to muddy the waters further, a second study found that the antidepressants did not impair tamoxifen's cancer-fighting powers.

Nevertheless, authors from both reports are recommending that women who have had breast cancer explore other ways to treat hot flashes.

Outside experts agreed.

"Women should talk to their medical oncologist about what antidepressant they're and what hormone therapy they're on, and make sure they're not one of the ones we're worried about," said Dr. Kelly Marcom, a breast oncologist with the Duke Comprehensive Cancer Center and director of the Duke Hereditary Cancer Clinic, in Durham, N.C.

Many breast cancer survivors take the drug tamoxifen to reduce their odds for recurrence. But tamoxifen often causes hot flashes, a side effect that can be controlled with selective serotonin reuptake inhibitor (SSRI) antidepressants such as paroxetine (Paxil) or fluoxetine (Prozac). Besides working on the neurotransmitter serotonin, these drugs inhibit an enzyme called 2D6, necessary to convert tamoxifen into its main active metabolite, endoxifen.

Women who have a gene mutation preventing the formation of 2D6 do not reap the same benefits from tamoxifen as women without the mutation, the researchers noted. Moreover, drugs that inhibit the formation of 2D6 may result in lower levels of endoxifen, although the clinical implications of that remain unclear.

The U.S. Food and Drug Administration is still weighing whether or not to add a caution about the gene variation to the tamoxifen label.

In one of the studies, Medco, a U.S. pharmacy benefits management company, reviewed the medical records of 10.7 million members of a health plan. That analysis turned up 945 women taking tamoxifen and 353 taking tamoxifen plus an SSRI/2D6 inhibitor, most commonly Prozac and Paxil.

Both groups of women, whose average age was in the early 50s, had followed similar treatment courses.

Women taking both drugs had a 13.9 percent chance of their breast cancer returning over two years, vs. just 7.5 percent of those receiving tamoxifen alone; that translates into an almost twofold increase in risk.

The second study, conducted by researchers at Leiden University Medical Center in the Netherlands, collected information on almost 2,000 breast cancer patients using tamoxifen, 215 of whom had used an SSRI/2D6 inhibitor at some point during their tamoxifen treatment.

That study found no increased risk of a breast recurrence in women taking both drugs. However, the authors pointed out, the number of women taking both drugs was small -- good enough reason for women and doctors to search for other options to combat hot flashes.

The Medco findings should serve as a warning but not a confirmation of any real danger to patients, one expert said.

"It's a study that is very difficult to interpret because it's really not complete enough information," said Dr. Claudine Isaacs, director of the clinical breast cancer program at Georgetown's Lombardi Comprehensive Cancer Center in Washington, D.C. "It raises a concern about this, and there's a scientific rationale to be concerned about. We can't say anything conclusively but there are options, other types of antidepressants, other types of medications, that don't have that impact. The cautious thing to do is to choose other medications while trying to sort this out."

Marcom agreed. He also noted that breast cancer-inhibiting medications called aromatase inhibitors, which include letrozole (Femara) and exemestane (Aromasin), "are one possible alternative to tamoxifen. There are also genotyping issues -- how different individuals metabolize the various drugs. This is not standard of care but it can be checked."

More information

There's more on tamoxifen at the U.S. National Cancer Institute.



SOURCES: Claudine Isaacs, director, clinical breast cancer program, Georgetown's Lombardi Comprehensive Cancer Center, Washington, D.C.; P. Kelly Marcom, M.D., breast oncologist, Duke Comprehensive Cancer Center, and director, Duke Hereditary Cancer Clinic, Durham, N.C.; May 30, 2009, presentations, American Society of Clinical Oncology annual meeting, Orlando, Fla.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Are we cherry picking participants for studies of antidepressants?
2. Divorce, antidepressants, or weight gain/loss can add years to your face
3. Divorce, Antidepressants, or Weight Gain/Loss Can Add Years to Your Face
4. SSRI Antidepressants May Lower Adult Suicide Risk
5. Zoloft, Lexapro the Best of Newer Antidepressants
6. Certain Antidepressants Ease Fibromyalgia Symptoms
7. Pregnancy study finds strong association between two antidepressants and heart anomalies
8. 2nd Generation Antidepressants Prove Effective
9. Response rates to antidepressants differ among English- and Spanish-speaking Hispanics
10. Lyriana Announces Antidepressants Now Linked to Declining Libido in Women
11. Do Antidepressants Make Bones Brittle?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer
(Date:5/31/2016)... ... , ... The successful implementation of “lean manufacturing” in various fields has inspired ... different challenges compared to manufacturing environments. , In order to provide a way ... developed the Lean Lab Checklist . This checklist will help users gain an ...
(Date:5/31/2016)... ... May 31, 2016 , ... WaterField Designs, an innovative leader ... the waxed-canvas and leather Duo Dopp Kit , the ideal gift upgrade for ... nylon, the Duo is smartly designed for Dad’s grooming routine. Two compartments ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Orthopaedic Research ... committee members: , David G. Lewallen, MD, began his term as president in ... Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve ...
(Date:5/31/2016)... Clearwater, FL (PRWEB) , ... May 31, 2016 , ... ... for its innovative herbal energy pouches, on World No Tobacco Day . ... in select retail locations later on this summer. , The new flavor is ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta attained his Doctor ... in the class of 1986, where he graduated in the top ten percentile of ... in Livingston since 1989. He has been a member in good standing for thirty ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 Eye ... parents of premature babies to seek an eye examination ... blinding condition     Moorfields Eye Hospital ... in London , has identified premature babies as ... problems, because of their particular vulnerability to retinopathy of prematurity (ROP). ...
(Date:5/27/2016)... According to the 2016 report, ... ambulatory blood pressure monitoring system market growth. With aging, ... to respond to different pressure rates, leading to hypertension ... various cardiovascular disorders such as heart failure, stroke, coronary ... growing in prevalence each year. WHO estimates that 17 ...
(Date:5/27/2016)... , May 27, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today ... be presenting at two upcoming investor conferences: SeeThru ... Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt ...
Breaking Medicine Technology: